Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05397678 |
| Other study ID # |
BCGSTRAIN IV |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
Phase 4
|
| First received |
|
| Last updated |
|
| Start date |
October 21, 2022 |
| Est. completion date |
October 2024 |
Study information
| Verified date |
January 2024 |
| Source |
Bandim Health Project |
| Contact |
Peter Aaby, Professor |
| Phone |
966620077 |
| Email |
p.aaby[@]bandim.org |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of Hospital
Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare vaccination with Bacillus
Calmette-Guérin (BCG) Danish strain (AJ Vaccines, Copenhagen 1331 strain) versus BCG-Bulgaria
(BB-NCIPD, BCG-SL 222 Sofia strain) 1:1 in 15,000 infants with respect to mortality,
morbidity and case-fatality rate during hospital admission. The trial will also examine the
association between BCG strains and BCG skin reaction kinetics and characteristics.
As a secondary aim, this large study will be used to further evaluate the role of maternal
BCG immune priming for overall health, since there are indications that the maternal BCG scar
status influences offspring health outcomes.
Description:
This two-year outcome assessor-blinded RCT will be conducted at the maternity ward of
hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare BCG-Denmark versus
BCG-Bulgaria 1:1 in 15,000 infants with respect to mortality, morbidity and case-fatality
rate during hospital admission.
The trial will also examine the association between BCG strains and BCG skin reaction
kinetics and characteristics.
HYPOTHESES
The investigators aim to investigate the following hypotheses:
1. Compared with BCG-Bulgaria, receiving BCG-Denmark is associated with
1. a 35% reduction in all-cause deaths and
2. a 50% lower case-fatality rate for hospitalized infants.
2. BCG-vaccinated infants have lower mortality and in-hospital case-fatality risk if the
mother has a BCG scar than if the mother does not have a BCG scar.
3. BCG-Denmark is associated with more favorable early-life BCG skin reaction kinetics
(prevalence, type, size)
METHODS Setting: The RCT will be carried out by the BHP in close collaboration with the
Maternity Ward of HNSM in Bissau. A dedicated BHP team registers births and oversees all
vaccinations at the Ward, where BHP has conducted a series of RCTs since 2002, with the aim
of improving early-life health outcomes. The BHP maintains a Health and Demographic
Surveillance System (HDSS) comprising approx. 100,000 individuals in the capital Bissau.
Inclusion: Neonates born at the HNSM Maternity Ward and neonates referred to the ward for
vaccination from the adjacent Pediatric Ward, the Neonatal Intensive Care Ward and the
Maternity Center receive their neonatal vaccines at the Maternity Ward and are eligible for
participation in the study. Mothers/guardians to infants eligible for the study will receive
an oral study explanation in Portuguese Creole and a written explanation in Portuguese.
Provided that oral consent is obtained, the mother/guardian signs a written consent form; if
the mother or guardian is illiterate, a fingerprint can be provided to confirm participation.
The family can request that their child leaves the trial at any time. Infants that are not
eligible for participation or whose mother/guardian declines participation will be registered
and provided the routine vaccinations by the study team (standard practice). Information on
maternal and paternal BCG scar status, scar size, mid-upper-arm circumference and
socioeconomic factors will be collected during the inclusion procedure.
Telephone contact information for the mother, the father and family members and/or persons
living in the same house are recorded at inclusion. Infants for whom only 0 or 1 telephone
numbers are available at inclusion will be transported home by a BHP car, when possible, to
secure more telephone numbers, provided consent has been obtained and the family lives in
greater Bissau. Similarly, infants from the HDSS with incomplete address information will be
transported home, when possible, to correctly register the address of the family house. BCG
will be provided at discharge for all infants at the ward and a sticker is placed on the
vaccination card of all neonates assessed for eligibility to the study, regardless of
participation. This sticker provides access to free consultations at three health centers
located in the HDSS with essential drugs provided free of charge.
Randomization: Following informed consent, the mother selects, from a stack of envelopes, a
closed envelope that contains a sealed randomization lot indicating allocation to either
BCG-Denmark or BCG-Bulgaria. The mother, inclusion assistant and vaccinator will thus not be
blinded to the intervention allocation. The envelope and randomization lot are opened, and
the lot is stapled to the inclusion form. Randomization lot envelopes are prepared by a
senior staff supervisor in separate bundles of 40 for each sex.
Vaccination: The infant is vaccinated intradermally with 0.05 ml of the allocated BCG strain
in the left upper deltoid, followed by vaccination with OPV. OPV is provided via the National
Vaccination Program; if OPV is in shortage, only BCG vaccination will be provided.
Follow-up: All assistants assessing outcomes during the follow-up procedures outlined below
will be blinded to the randomization allocation.
Follow-up takes place through three mechanisms:
A) All enrolled infants with a telephone number recorded at inclusion: Family telephone
interview at one week, six weeks and six months of age.
Families are telephoned to register dates and outcomes of hospital admissions and whether the
child is alive. If the child died, the mother/guardian is briefly asked about symptoms and
whether the death occurred at home or at a hospital. Information on adherence to the six-week
vaccination schedule, infant BCG skin reaction status (yes/no, type of skin reaction) and
adverse events is also collected. Priority will be given to interview the mother or father of
the child when possible. Based on previous experiences summarized in Table 5, 99% of families
provided at least one telephone number at inclusion and the overall follow-up rate by
telephone is approx. 95%.
B) Cohort of BHP HDSS infants: home visit during the first two months of life. With the
proposed sample size of 15,000 infants and an estimated 15% residing in the HDSS study area,
the study will include approximately 2,250 children from the HDSS. In addition to follow-up
within the routine surveillance system maintained by the investigators, these children will
receive one additional home visit between one week and eight weeks of age. At the visit,
trial assistants will collect data on mortality, morbidity, BCG skin reaction status, type
and size, adverse events and maternal and paternal BCG scar status and size (if not collected
at inclusion). The visit is conducted between one and eight weeks of age to collect data
regarding the kinetics of early BCG skin reactions (prevalence, type).
C) All enrolled infants: Registration of admissions and consultations at the HNSM pediatric
ward.
Admissions, diagnoses and outcomes at the pediatric ward are documented by a BHP team on all
days of the year. Parental names and telephone numbers are registered for all admissions. For
approximately 60% of infant admissions, data from the child's health card is documented
during the admission, ensuring registration of the child's unique study ID for later data
linkage. To identify the remaining admissions not registered with the unique study ID, a
previously validated standardized systematic database linkage and search algorithm will be
applied.
Sample size:
There are approx. 7,000 childbirths per year at the maternity ward of the HNSM and an
additional 500-600 neonates not born at HNSM are vaccinated there each year. With an expected
monthly inclusion rate of 600 infants based on previous experiences, the investigators expect
to be able to include at least 15,000 children, i.e. 7,500 in each BCG strain group, during
an expected timeframe of approx. two years for inclusion procedures and an additional six
months for follow-up procedures.
Analyses:
The mortality and morbidity data will be analyzed as intention-to-treat in Cox regression
models with age as the underlying time variable, i.e. with complete adjustment for age.
In-hospital case-fatality rates between BCG strains will be compared using binomial
regression. In case an OPV or other campaigns with potential immune stimulatory effects
occurs during the study period, the main comparison of the two strains and of the effects of
maternal BCG scarring on infant outcomes will be conducted by censoring all children on the
first day of the campaign, to exclude any interaction of the campaign with the BCG strains.
As sensitivity analyses, an analysis where events occurring on the day of BCG vaccination are
omitted will be conducted. An analysis of main outcomes excluding neonates that were admitted
at the pediatric or NICU ward before inclusion will also be conducted. In case there are
shortages of OPV and thus neonates included that do not receive OPV-0, an analysis of main
outcomes by receipt of OPV-0 will be conducted.
The investigators will conduct explorative analyses evaluating effects of the BCG strains by
post-vaccination wheal size (<5mm vs >5mm), sex, and vaccinator.
All analyses will be conducted overall and stratified by maternal BCG scar status and sex.
The investigators will conduct an analysis of the independent effect of the maternal scar
status on trial outcomes with adjustment for possible associations between socioeconomic
factors and maternal BCG scarring that can also affect the mortality risk in the offspring.
Trial vaccines:
In the event that BCG-Denmark and/or BCG-Bulgaria is available via the Nationwide Program of
Vaccination (EPI) in Guinea-Bissau and thus provided to the BHP team at HNSM, these vaccines
will be considered equivalent and used as trial vaccines. If not available, the BCG vaccines
will be acquired from AJ Vaccines (BCG-Denmark, Copenhagen 1331 strain) and BB-NCIPD
(BCG-Bulgaria, BCG-SL 222 Sofia strain). If there are unforeseen difficulties procuring the
trial vaccines, BCG-Bulgaria can be substituted with either of the following genetically
similar strains: BCG-Russia (Russian BCG-I strain, Microgen, Russia) or BCG-Russia (Serum
Institute of India, Pune, India). BCG-Denmark can be substituted with either of the
following: BCG-GreenSignal (Copenhagen 1331, GreenSignal Bio Pharma), BCG-Chennai (Copenhagen
1331, BCG Vaccine Laboratory Chennai), or BCG-Tokyo (Tokyo 172-1 strain, Japan BCG
laboratory).
Ethical considerations:
The proposed study will randomize children to two BCG strains that are prequalified and
distributed by UNICEF and used in both Guinea-Bissau and the rest of the world. Previous
studies from the investigators have shown that providing BCG vaccination at discharge is safe
and beneficial. Oral and written informed consent will be obtained in all cases. The BHP
offers medical consultations at two HDSS health centers to all infants assessed for
eligibility, independent of eligibility or whether the mother/guardian chose to participate
or not. Essential medications are available through the PIMI program free-of-charge, but in
case they run out or the PIMI program is discontinued during the trial, BHP offers essential
drugs as a back-up. The mothers are encouraged to bring their child for consultation at a
health center if their child develops lymphadenitis.
The study protocol will be submitted for approval by the Ethical Committee in Guinea-Bissau
and to the Central Ethical Committee in Denmark for consultative approval. A local clinical
monitor will be appointed to oversee the study.
